BACKGROUND: One-year results of the VBLOC @entity4989 study found that intermittent vagal blocking (VBLOC therapy) was safe among subjects with @entity28 and @entity6 ( @entity6 ) and led to significant @entity353 and improvements in glycemic parameters and cardiovascular risk factors. Longer-term data are needed to determine whether the results are sustained. METHODS: VBLOC @entity4989 is a prospective, observational study of 28 subjects with @entity6 and body mass index (BMI) between 30 and 40  kg/m(2) to assess mid-term safety and @entity353 and improvements in glycemic parameters, and other cardiovascular risk factors with VBLOC therapy. Continuous outcome variables are reported using mixed models. RESULTS: At 24  months, the mean percentage of excess @entity353 was 22  % (95  % CI, 15 to 28, p   <   0.0001) or 7.0  % total body @entity353 (95  % CI, 5.0 to 9.0, p   <   0.0001). Hemoglobin A1c decreased by 0.6 percentage points (95  % CI, 0.2 to 1.0, p   =   0.0026) on average from 7.8  % at baseline. Fasting plasma @entity413 declined by 15  mg/dL (95  % CI, 0 to 29, p   =   0.0564) on average from 151  mg/dL at baseline. Among subjects who were @entity101 at baseline, systolic blood pressure declined 10  mmHg (95  % CI, 2 to 19, p   =   0.02), diastolic blood pressure declined by 6  mmHg (95  % CI, 0 to 12, p   =   0.0423), and mean arterial pressure declined 7  mmHg (95  % CI, 2 to 13, p   =   0.014). Waist circumference was significantly reduced by 7  cm (95  % CI, 4 to 10, p   <   0.0001) from a baseline of 120  cm. The most common adverse events were mild or moderate @entity158 , and @entity1142 . CONCLUSIONS: Improvements in @entity28 and glycemic control were largely sustained after 2  years of treatment with VBLOC therapy with a well-tolerated risk profile.

Intermittent Vagal Nerve Block for Improvements in Obesity, Cardiovascular Risk Factors, and Glycemic Control in Patients with XXXX : 2-Year Results of the VBLOC @entity4989 Study.

@entity353 :: ('MESH:D015431', 'Disease') :: ['weight loss'] @entity6 :: ('MESH:D003920', 'Disease') :: ['T2DM', 'type 2 diabetes mellitus'] @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertensive'] @entity4989 :: ('28508', 'Gene') :: ['DM2'] @entity158 :: ('MESH:D010146', 'Disease') :: ['heartburn, implant site pain'] @entity1142 :: ('MESH:D003248', 'Disease') :: ['constipation'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']
@entity6 :: (MESH:D003920,Disease) :: ['Type 2 Diabetes Mellitus']
